Try our beta test site
19 studies found for:    melanoma metastatic liver | Open Studies
Show Display Options
Rank Status Study
1 Recruiting Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases
Conditions: Uveal Melanoma;   Hepatic Metastases
Interventions: Device: SIR-Spheres® Yttrium 90;   Drug: ipilimumab;   Drug: nivolumab
2 Recruiting Ipilimumab 60-month Pharmacovigilance Protocol for Advanced Melanoma Patients Who Are Hepatitis B and/or Hepatitis C Virus Positive in Taiwan
Conditions: Advanced Melanoma;   Hepatitis B;   Hepatitis C
Intervention:
3 Recruiting Safety Study of Talimogene Laheraprepvec Injected Into Hepatocellular Carcinoma and Metastatic Liver Tumors
Conditions: Hepatocellular Carcinoma;   Liver Metastases
Intervention: Drug: Talimogene Laherparepvec
4 Recruiting PI Pembro in Combination With Stereotactic Body Radiotherapy for Liver Metastatic Colorectal Cancer
Conditions: Colorectal Cancer;   Colorectal Adeonocarcinoma;   Stage IVA Colorectal Cancer;   Stage IVB Colorectal Cancer;   Metastatic Carcinoma in the Liver
Interventions: Radiation: Stereotactic body radiotherapy (SBRT);   Drug: Pembrolizumab
5 Recruiting A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Solid Tumors
Conditions: Metastatic Colorectal Cancer;   Metastatic Renal Cell Carcinoma;   Metastatic Melanoma;   Brain Metastasis;   Locally Advanced or Metastatic Pancreatic Cancer;   Locally Advanced or Metastatic Breast Cancer
Interventions: Biological: Toca 511;   Drug: Toca FC
6 Recruiting Sorafenib and Radioembolization With Sir-Spheres® for the Treatment of Metastatic Ocular Melanoma
Condition: Ocular Melanoma
Interventions: Drug: Sorafenib;   Device: Radioembolization with SIR-Spheres® (Yttrium Microspheres)
7 Recruiting Transarterial Radioembolisation in Comparison to Transarterial Chemoembolisation in Uveal Melanoma Liver Metastasis
Condition: Uveal Melanoma
Interventions: Procedure: SIRT;   Procedure: DSM-TACE
8 Recruiting Propranolol Hydrochloride in Treating Patients With Locally Recurrent or Metastatic Solid Tumors That Cannot Be Removed By Surgery
Conditions: Male Breast Cancer;   Recurrent Melanoma;   Stage IV Breast Cancer;   Stage IV Melanoma;   Stage IV Ovarian Epithelial Cancer;   Stage IV Ovarian Germ Cell Tumor;   Unspecified Adult Solid Tumor, Protocol Specific;   Hepatocellular Carcinoma
Interventions: Drug: propranolol hydrochloride;   Other: Correlative Studies
9 Recruiting Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
Conditions: Breast Carcinoma;   Carcinoma of Unknown Primary Origin;   Endometrial Carcinoma;   Esophageal Carcinoma;   Lung Carcinoma;   Malignant Head and Neck Neoplasm;   Melanoma;   Ovarian Carcinoma;   Renal Pelvis and Ureter Urothelial Carcinoma;   Testicular Lymphoma
Interventions: Drug: Carboplatin;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Other: Pharmacological Study;   Drug: Veliparib
10 Recruiting Collecting Solid Tumor Tissue to Identify New Treatments
Conditions: Gastrointestinal Cancer;   Liver Cancer;   Pancreatic Cancer;   Melanoma
Intervention:
11 Recruiting A Study of RGX-104 in Patients With Advanced Solid Malignancies and Lymphoma
Condition: Malignant Neoplasms
Intervention: Drug: RGX-104
12 Recruiting Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
Conditions: Glioma;   Lymphoma;   Metastatic Malignant Solid Neoplasm;   Neuroendocrine Neoplasm;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Bladder Carcinoma;   Recurrent Breast Carcinoma;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Colorectal Carcinoma;   Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma;   Recurrent Head and Neck Carcinoma;   Recurrent Lung Carcinoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Melanoma;   Recurrent Pancreatic Carcinoma;   Recurrent Prostate Carcinoma;   Recurrent Renal Cell Carcinoma;   Recurrent Thyroid Gland Carcinoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma;   Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Stage III Lung Cancer;   Stage III Pancreatic Cancer;   Stage III Prostate Cancer;   Stage III Renal Cell Cancer;   Stage III Soft Tissue Sarcoma;   Stage IIIA Breast Cancer;   Stage IIIA Colorectal Cancer;   Stage IIIA Skin Melanoma;   Stage IIIB Breast Cancer;   Stage IIIB Colorectal Cancer;   Stage IIIB Skin Melanoma;   Stage IIIC Breast Cancer;   Stage IIIC Colorectal Cancer;   Stage IIIC Skin Melanoma;   Stage IV Breast Cancer;   Stage IV Lung Cancer;   Stage IV Pancreatic Cancer;   Stage IV Prostate Cancer;   Stage IV Renal Cell Cancer;   Stage IV Skin Melanoma;   Stage IV Soft Tissue Sarcoma;   Stage IVA Colorectal Cancer;   Stage IVB Colorectal Cancer;   Unresectable Solid Neoplasm
Interventions: Other: Pharmacological Study;   Drug: Romidepsin
13 Recruiting Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin
Conditions: Pleural Mesothelioma Malignant Advanced;   Peritoneal Mesothelioma Malignant Advanced;   Non-squamous Non-small Cell Lung Carcinoma Stage IIIB/IV (NSCLC);   Metastatic Uveal Melanoma;   Hepatocellular Carcinoma (HCC);   Glioma;   Sarcomatoid Cancers
Intervention: Drug: ADI-PEG 20
14 Recruiting Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
Conditions: Metastatic Colorectal Cancer;   Metastatic Gastric Cancer;   Metastatic Pancreatic Cancer;   Metastatic Hepatocellular Carcinoma;   Metastatic Cholangiocarcinoma
Interventions: Biological: Young TIL;   Drug: Aldesleukin;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Pembrolizumab
15 Recruiting Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
Conditions: Hematological Neoplasms;   Non-Hodgkin's Lymphoma;   Hodgkin's Lymphoma;   Lymphoma;   Multiple Myeloma;   Acute Myeloid Leukemia;   Leukemia;   Myelodysplastic Syndromes;   Neoplasms;   Melanoma;   Breast Cancer;   Metastatic Breast Cancer;   Non-Small Cell Lung Cancer;   Small Cell Lung Cancer;   Renal Cell Carcinoma;   Glioblastoma Multiforme;   Osteosarcoma;   Sarcoma;   Thyroid Cancer;   Genitourinary
Interventions: Drug: CC-486;   Drug: Vidaza
16 Recruiting Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566
Condition: Neoplasms
Interventions: Drug: PF-04518600;   Drug: PF-04518600 plus PF-05082566
17 Recruiting Cancer Research Repository for Individuals With Cancer Diagnosis, High Risk Individuals, and Individuals With No History of Cancer (Control)
Conditions: Pancreatic Cancer;   Thyroid Cancer;   Lung Cancer;   Esophageal Cancer;   Thymus Cancer;   Colon Cancer;   Rectal Cancer;   GIST;   Anal Cancer;   Bile Duct Cancer;   Duodenal Cancer;   Gallbladder Cancer;   Gastric Cancer;   Liver Cancer;   Small Intestine Cancer;   Peritoneal Surface Malignancies;   Familial Adenomatous Polyposis;   Lynch Syndrome;   Bladder Cancer;   Kidney Cancer;   Penile Cancer;   Prostate Cancer;   Testicular Cancer;   Ureter Cancer;   Urethral Cancer;   Hypopharyngeal Cancer;   Laryngeal Cancer;   Lip Cancer;   Oral Cavity Cancer;   Nasopharyngeal Cancer;   Oropharyngeal Cancer;   Paranasal Sinus Cancer;   Nasal Cavity Cancer;   Salivary Gland Cancer;   Skin Cancer;   CNS Tumor;   CNS Cancer;   Mesothelioma;   Breastcancer;   Leukemia;   Melanoma;   Sarcoma;   Unknown Primary Tumor;   Multiple Myeloma;   Ovarian Cancer;   Endometrial Cancer;   Vaginal Cancer
Intervention:
18 Recruiting Survivorship Promotion In Reducing IGF-1 Trial
Conditions: Breast Cancer;   Prostate Cancer;   Lung Cancer;   Colon Cancer;   Melanoma of Skin;   Endometrial Cancer;   Liver Cancer;   Pancreatic Cancer;   Rectal Cancer;   Kidney Cancer;   Other Solid Malignant Tumors
Interventions: Drug: Metformin;   Behavioral: Coach Directed Behavioral Weight Loss;   Behavioral: Self-control weight loss
19 Recruiting Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms
Conditions: AIDS-Related Non-Hodgkin Lymphoma;   Classical Hodgkin Lymphoma;   HIV Infection;   Locally Advanced Malignant Neoplasm;   Metastatic Malignant Neoplasm;   Recurrent Hepatocellular Carcinoma;   Recurrent Hodgkin Lymphoma;   Recurrent Kaposi Sarcoma;   Recurrent Malignant Neoplasm;   Recurrent Melanoma of the Skin;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Non-Small Cell Lung Carcinoma;   Refractory Hodgkin Lymphoma;   Refractory Malignant Neoplasm;   Solid Neoplasm;   Stage IIIA Hepatocellular Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIA Skin Melanoma;   Stage IIIB Hepatocellular Carcinoma;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IIIB Skin Melanoma;   Stage IIIC Hepatocellular Carcinoma;   Stage IIIC Skin Melanoma;   Stage IV Non-Small Cell Lung Cancer;   Stage IV Skin Melanoma;   Stage IVA Hepatocellular Carcinoma;   Stage IVB Hepatocellular Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab

Study has passed its completion date and status has not been verified in more than two years.